QualityDipStocks / Health Care · Pharmaceuticals
Viatris VTRS
Outside our quality screen, so we don’t track its dips. It’s 1% below its 52-week high.
Outside our quality screen, trading well below our fair value estimate, 4% over its Market Value.
- Fair value est.
- $26.63+40%
- Market Value
- $18.24price +4%
- Off 52-wk high
- −1%
- Risk vs market
- Lowbeta 0.68
3 bullish · 5 bearish See why
Key levels
Every level vs today’s $19.04
- 52-wk lowlowest close, 1 year$10.11−46.9%
- Market Valueavg paid since Oct 8$18.24−4.2%
- PriceFri Oct 30 close$19.04you are here
- 52-wk highhighest close, 1 year$19.20+0.8%
- Fair value est.base case$26.63+39.9%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 3.0% ±2 points. Bear = 10.5% and 1.0%; bull = 8.5% and 5.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is below even the bear case.
What the price implies To be worth today’s price, VTRS’s free cash flow would need to shrink about 3% a year for five years; our estimate uses 3%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much VTRS moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 2.5× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.68
- Volatility
- 32% vs 13% SPY
- Correlation SPY
- 0.27
- Correlation QQQ
- 0.14
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 3 of 5
ValuationOur DCF fair value estimate is $26.63, 40% above the price.
ValuationFree-cash-flow yield of 8.8% (price / FCF 11.3×): $2.0B of free cash in the last 12 months.
Balance sheetPaid down debt: $14.4B at FY2025, 21% less than at FY2023.
Top bearish points 5 of 5
ProfitabilityOperating margin narrowed to −18.6% in FY2025 from 5.0% in FY2023 (SEC filings).
Balance sheetOperating income covers interest only -0.2× over the last 12 months.
ProfitabilityLost $411M over the last 12 months (net income, SEC filings).
ProfitabilityLoses money at the operating line: −1% operating margin over the last 12 months.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%; net debt 4.9× EBITDA (limit 3×).
Who’s talking about it
Notable investors, executives, analysts and public figures on Viatris in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
All fundamentals
FCF yield 8.8% · Sales +4%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- 11.3×
- FCF yield
- 8.8%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 1.50×
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $22.1Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $14.7B
- Sales growth, 12 months
- +4.4%vs the 12 months before
- Sales growth, 3 yrs
- −4.2%/yrfrom FY2022
- Diluted EPS, 12 months
- −$0.37
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$411M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 34.8%
- Operating margin
- −0.6%
- Net margin
- −2.8%
- FCF margin
- 13.3%
- Return on equity
- n/anot reported in its SEC filings
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- n/anot reported in its SEC filings
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- -0.2×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $2.0B
- FCF growth, 12 months
- +12%
- Dividend yield
- n/ano dividend payments tagged
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $300M1.4% of market cap
- Share count, 1 year
- −0.8%diluted shares vs a year ago
- Stock-based comp
- $172M
Trailing 12 months to Jun 30, 2026. From Viatris’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $26.63 · MV $18.24 · FCF value $38.98
Assumes 3.0% growth for 5 years (revenue grew -4.2% a year FY22–FY25; floored at 3%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $1.68 a share (trailing 12 months to Jun 30, 2026), from the 10-Q filed Aug 6, 2026. Net debt $12.5B, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 64 · 5 days +5.8%
The business
FCF $1.8B · Sales +5%
- Free cash flow, 12 months$1.8B
- Free-cash-flow yield8.2%
- Free-cash-flow margin12%
- Gross margin35%
- Operating margin1%
- Return on invested capital0%
- Return on equity−3%
- Sales growth (latest quarter vs year-ago quarter)+5%
- Net debt / EBITDA4.9×
Next report
Nov 5
- DateThu Nov 5, before the open
- Consensus EPS$0.64
- Year-ago EPS$0.67
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
VTRS is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.